These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists]. Rascol O Rev Neurol (Paris); 1999 Jan; 155(1):35-42. PubMed ID: 10093846 [No Abstract] [Full Text] [Related]
43. Clozapine: new preparation. A last resort for parkinsonian patients with psychosis. Prescrire Int; 2002 Feb; 11(57):1-6. PubMed ID: 11985366 [TBL] [Abstract][Full Text] [Related]
44. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
53. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Merims D; Giladi N Parkinsonism Relat Disord; 2008; 14(4):273-80. PubMed ID: 17988927 [TBL] [Abstract][Full Text] [Related]
54. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Stocchi F Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046 [TBL] [Abstract][Full Text] [Related]
55. Clozapine prevents recurrence of psychosis in Parkinson's disease. Factor SA; Brown D Mov Disord; 1992; 7(2):125-31. PubMed ID: 1350059 [TBL] [Abstract][Full Text] [Related]
56. Features associated with the development of hallucinations in Parkinson's disease. Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542 [TBL] [Abstract][Full Text] [Related]
57. Treatment of Parkinson's disease--where do we go from here? Suchowersky O Nat Clin Pract Neurol; 2006 Sep; 2(9):461. PubMed ID: 16932605 [No Abstract] [Full Text] [Related]
58. Drug treatment of Parkinson's disease. Callaghan N Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850 [No Abstract] [Full Text] [Related]